Board of Directors

Wolfram Carius, Ph.D.

Executive Vice President Pharmaceuticals Product Supply, Bayer AG

Prof. Wolfram Carius is the Head of Pharmaceuticals Product Supply since September 1, 2016 (Chemicals, Pharma, Biotech, Devices) at Bayer AG and is a member of the Executive Committee for Bayer Pharmaceuticals. He is based in Berlin, Germany. Prior to joining Bayer, Wolfram was a corporate senior vice president and member of the global leadership team at Sanofi Genzyme for two years. Before that, he worked for Boehringer Ingelheim from 1987 to the end of 2013, eventually becoming responsible for that company’s worldwide chemical, pharmaceutical, and biopharma production network. In his 30 years in the pharmaceutical industry he has worked in Asia, South America and Europe. In 2009, the Biberach University of Applied Sciences awarded him the title of honorary professor in recognition for his long and exceptional service.

Jürgen Eckhardt, M.D.

Head, Leaps by Bayer

Dr. Jürgen Eckhardt is Head of Leaps by Bayer, which focuses on new, cross-divisional technologies with fundamental breakthrough potential. He is also a member of the Bayer R&D Executive Committee. Before joining Bayer, Jürgen was a venture capitalist for 14 years and head of the venture capital franchise at Bellevue/BB Biotech in Switzerland. He raised and invested several funds in biotech, medical devices, and healthcare services in Europe and the U.S. Dr. Eckhart received his M.D. from the University of Basel, Switzerland and his MBA from INSEAD in Fontainebleau, France.

Joerg Moeller, M.D., Ph.D.

Head, Research & Development

As of January 2018, Joerg Moeller has been serving as Head of Research & Development, Pharmaceuticals and a member of the Executive Committee of Bayer’s Pharmaceuticals Division. Joerg Moeller, M.D., Ph.D., joined Bayer AG in 1993 from academic medicine at Ruhr-University Bochum, Germany. Initially being responsible for global late stage development of a cardio-vascular compound, he became responsible for cardiovascular new business development in 1996. From 1998 until the end of 2001, Dr. Moeller held positions of increasing responsibility in clinical development at Bayer Corporation, West Haven, CT (USA) and at Bayer Inc., HealthCare Division, Toronto (Canada). In March 2003, Dr. Moeller became Head, Global Clinical Development at Bayer HealthCare AG, Pharmaceuticals Division. Joerg Moeller was named Head of Global Development on Feb 1, 2014 and became a member of the Pharmaceuticals Division Executive Committee in 2016.

EMILE NUWAYSIR, Ph.D.

President and CEO, Board Member

Emile Nuwaysir, Ph.D., joined BlueRock in Feb 2017, bringing nearly 20 years of experience in creating and guiding innovative life science companies from startup stage to fully integrated biotech companies. Prior to BlueRock, he was the President of a regenerative medicine division of Fujifilm (Cellular Dynamics International, Inc. – a Fujifilm Company) and President of Opsis Therapeutics, a biotech developing cell therapies for the retina. Prior to Fujifilm, he was COO of Cellular Dynamics International (CDI) where he helped manage CDI’s growth from a pre-revenue startup to a publicly traded Company on NASDAQ and through the ultimate acquisition of $307M by FujiFilm in 2015. Prior to CDI, he was CTO at Roche NimbleGen, a division of Roche Diagnostics, where he oversaw the product portfolio, Business Development and R&D. Prior to Roche, he was VP of Business Development at NimbleGen Systems where he helped build the company and its products, raise capital, prepare for an IPO, and manage a “dual-track” IPO process leading to the take-out sale by Roche for $282M in 2007. He currently also holds positions of vice-chairman for the Alliance for Regenerative Medicine, and founder and vice-chairman of Invenra, Inc. He completed his Ph.D. from the University of Wisconsin-Madison and postdoctoral fellowships at the National Institutes of Health and UNC-Chapel Hill.

Stefan Oelrich

President, Pharmaceuticals Division & Board Member of Bayer AG

Stefan Oelrich has been a member of the Board of Management of Bayer AG and Head of the Pharmaceuticals Division, headquartered in Berlin, Germany, since November 1, 2018. He is also responsible for the region Latin America. After graduating from high school in Paris, France, he joined Bayer AG as a commercial trainee in 1989 and qualified as a commercial assistant in 1991. Over the next 20 years, he held several positions of increasing responsibility in the health care business in Latin America, Europe and the United States. In 1998, after working in Argentina and Uruguay, Oelrich transferred to headquarters in Leverkusen for two years before assuming responsibility for Pharmaceuticals in Belgium. Between 2003 and 2005, he was Vice President of Marketing at Pharmaceuticals in the United States. He was subsequently appointed President of Healthcare and Diagnostics in France. In 2006, Oelrich returned to the United States as Senior Vice President and General Manager of Women’s Healthcare. In 2011, he joined Sanofi as General Manager in Germany, Switzerland and Austria. In 2015, Oelrich became head of Sanofi’s Diabetes and Cardiovascular business unit in Europe. At the same time, he served as Sanofi Europe Coordinator. In 2016, Oelrich became head of Sanofi’s global diabetes franchise. A year later, he was appointed Executive Vice President Diabetes & Cardiovascular on the Executive Committee of Sanofi. Since 2016, Oelrich has been a member of the Supervisory Board of the Berlin Institute of Health.